A groundbreaking urine test for lung cancer may soon be available through the NHS within the next five years, according to experts. This innovative test detects “zombie cells” that signal the early stages of cancer long before symptoms appear, potentially revolutionizing early diagnosis. Researchers from Cambridge University and Royal Papworth Hospital have successfully trialed the test on human urine samples, aiming to combat the leading cause of cancer-related deaths in the UK.
Lung cancer claims approximately 33,000 lives annually in the UK, with most cases diagnosed in advanced stages, making treatment challenging. The development of this new test could significantly improve early detection rates and ultimately save lives.
The test works by identifying senescent cells, also known as “zombie cells,” that linger in tissues and release harmful substances triggering inflammation. Researchers have created a sensor that interacts with a protein produced by these cells, releasing a detectable compound in urine to indicate their presence.
Professor Ljiljana Fruk of the University of Cambridge expressed optimism about the test’s potential impact, envisioning its widespread use in real patients across the NHS in the near future. While the sensor is yet to undergo human trials, it represents a crucial first step towards early detection of lung cancer, offering hope for more effective treatments.
The study, published in the journal Nature Ageing, highlights the validation of the biomarker in human tissue, demonstrating its potential for detecting various cancers and lung diseases. The research team is now exploring adaptations of the probe for detecting other types of cancer, including lung fibrosis.
Patrick Keely, a spokesperson for Cancer Research UK, which funded the research, emphasized the significance of technological advancements in research, praising the new urine test as a valuable tool for detecting lung cancer at its earliest stages.
The development of this urine test marks a significant advancement in the fight against lung cancer, providing hope for improved outcomes and a brighter future for patients at risk of this devastating disease.